Th-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid–polymer hybrid nanoparticle: Biodistribution and toxicity assessment of encapsulated amphotericin B

Asthana, Shalini; Jaiswal, Anil K.; Gupta, Pramod; Dube, Anuradha; Chourasia, Manish K.

doi:10.1016/j.ejpb.2014.11.019

Cited by 53 publications

(21 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Asthana and co-workers [208] formulated cationic Sta lipid-polymer hybrid nanoparticles (LPNPs) which presented characteristics of polymeric NPs and liposomes that allowed high EE, sustained drug release profile, and good tolerability [208]. The results evidenced high antifungal efficacy in vitro against intracellular amastigotes of L. donovani, considering the high uptake of LPNPs by macrophages, the rapidity of plasma clearance, and the significant drug allocation in liver and spleen macrophages [208].…”

Section: Lipid-polymer Hybrid Nanoparticlesmentioning

confidence: 99%

“…Since the Sta pattern recognition receptors (PRR) are overexpressed by macrophages infected with Leishmania parasites, Sta can be selected as a ligand targeting PRR and phosphatidylserine on the macrophage surface. Thereby, Sta presence on the nanoparticles surface may also be considered a target moiety [208]. The presence of TPGS emulsifier in the formulation, easily removed from NP surface, was able to increase AmB loading and EE, and to prompt an AmB response even against drug-resistant leishmanial strains.…”

Section: Lipid-polymer Hybrid Nanoparticlesmentioning

confidence: 99%

See 1 more Smart Citation

Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy

2020

View full text Add to dashboard Cite

Amphotericin B (AmB), a broad-spectrum polyene antibiotic in the clinic for more than fifty years, remains the gold standard in the treatment of life-threatening invasive fungal infections and visceral leishmaniasis. Due to its poor water solubility and membrane permeability, AmB is conventionally formulated with deoxycholate as a micellar suspension for intravenous administration, but severe infusion-related side effects and nephrotoxicity hamper its therapeutic potential. Lipid-based formulations, such as liposomal AmB, have been developed which significantly reduce the toxic side effects of the drug. However, their high cost and the need for parenteral administration limit their widespread use. Therefore, delivery systems that can retain or even enhance antimicrobial efficacy while simultaneously reducing AmB adverse events are an active area of research. Among those, lipid systems have been extensively investigated due to the high affinity of AmB for binding lipids. The development of a safe and cost-effective oral formulation able to improve drug accessibility would be a major breakthrough, and several lipid systems for the oral delivery of AmB are currently under development. This review summarizes recent advances in lipid-based systems for targeted delivery of AmB focusing on non-parenteral nanoparticulate formulations mainly investigated over the last five years and highlighting those that are currently in clinical trials.

show abstract

Section: Lipid-polymer Hybrid Nanoparticlesmentioning

confidence: 99%

Section: Lipid-polymer Hybrid Nanoparticlesmentioning

confidence: 99%

Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy

2020

View full text Add to dashboard Cite

show abstract

“…The absorbance of each supernatant was determined at 545 nm. The RBCs were incubated with 0.5 w/v% Triton X-100 and PBS (pH 7.4) as positive and negative controls, respectively [51,52]. Percentage (%) hemolysis was calculated using the following equation: TIB-67™) were purchased from ATCC, UK.…”

Section: Experimental Design and Construction Of Box-behnken (Bbd) Dementioning

confidence: 99%

An integrated vitamin E-coated polymer hybrid nanoplatform: A lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect

et al. 2020

View full text Add to dashboard Cite

A platform capable of specifically delivering an antiviral drug to the liver infected with hepatitis B is a major concern in hepatology. Vaccination has had a major effect on decreasing the emerging numbers of new cases of infection. However, the total elimination of the hepatitis B virus from the body requires prolonged therapy. In this work, we aimed to target the liver macrophages with lipid polymer hybrid nanoparticles (LPH), combining the merit of polymeric nanoparticles and lipid vesicles. The hydrophilic antiviral drug, entecavir (E), loaded LPH nanoparticles were optimized and physicochemically characterized. A modulated lipidic corona, as well as, an additional coat with vitamin E were used to extend the drug release enhance the macrophage uptake. The selected vitamin E coated LPH nanoparticles enriched with lecithin-glyceryl monostearate lipid shell exhibited high entrapment for E (80.47%), a size � 200 nm for liver passive targeting, extended release over one week, proven serum stability, retained stability after refrigeration storage for 6 months. Upon macrophage uptake in vitro assessment, the presented formulation displayed promising traits, enhancing the cellular retention in J774 macrophages cells. In vivo and antiviral activity futuristic studies would help in the potential application of the ELPH in hepatitis B control.

show abstract

“…102 Stearylamine was selected for its cationic nature, biocompatibility, benign antiprotozoal activity, and immunopotentiation strength. LPNPs containing an interesting amount of AmpB (DL 9.8%, w/w) were reported.…”

mentioning

confidence: 99%

“…In vivo experiments demonstrated significantly stronger parasite growth inhibition (89.4%) in patients treated with AmpB-LPNPs than in those treated with carrier without stearylamine (63.6% inhibition), whereas 69.3% parasite inhibition was observed with the AmBisome formulation. 102 With regard to the active targeting approach, mannosebearing PLGA nano/microparticles have been designed to further improve macrophage targeting of antileishmanial agents. Mannose-grafted PLGA nanoparticles, with and without a PEG spacer, are reported to target AmpB; 103 the presence of PEG spacer resulted in a more efficient inhibition of parasites in comparison to both the one without spacer and the free drug.…”

mentioning

confidence: 99%

Nanostructured delivery systems with improved leishmanicidal activity: a critical review

Bruni¹,

Stella²,

Giraudo³

et al. 2017

IJN

View full text Add to dashboard Cite

Leishmaniasis is a vector-borne zoonotic disease caused by protozoan parasites of the genus Leishmania , which are responsible for numerous clinical manifestations, such as cutaneous, visceral, and mucocutaneous leishmaniasis, depending on the site of infection for particular species. These complexities threaten 350 million people in 98 countries worldwide. Amastigotes living within macrophage phagolysosomes are the principal target of antileishmanial treatment, but these are not an easy target as drugs must overcome major structural barriers. Furthermore, limitations on current therapy are related to efficacy, toxicity, and cost, as well as the length of treatment, which can increase parasitic resistance. Nanotechnology has emerged as an attractive alternative as conventional drugs delivered by nanosized carriers have improved bioavailability and reduced toxicity, together with other characteristics that help to relieve the burden of this disease. The significance of using colloidal carriers loaded with active agents derives from the physiological uptake route of intravenous administered nanosystems (the phagocyte system). Nanosystems are thus able to promote a high drug concentration in intracellular mononuclear phagocyte system (MPS)-infected cells. Moreover, the versatility of nanometric drug delivery systems for the deliberate transport of a range of molecules plays a pivotal role in the design of therapeutic strategies against leishmaniasis. This review discusses studies on nanocarriers that have greatly contributed to improving the efficacy of antileishmaniasis drugs, presenting a critical review and some suggestions for improving drug delivery.

show abstract

Th-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid–polymer hybrid nanoparticle: Biodistribution and toxicity assessment of encapsulated amphotericin B

Cited by 53 publications

References 50 publications

Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy

Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy

An integrated vitamin E-coated polymer hybrid nanoplatform: A lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect

Nanostructured delivery systems with improved leishmanicidal activity: a critical review

Contact Info

Product

Resources

About